Results 21 to 30 of about 2,029,665 (367)

Hepatocellular carcinoma and multidrug resistance: Past, present and new challenges for therapy improvement [PDF]

, 2015
Hepatocellular carcinoma (HCC) is the most common malignancy of the liver and the third cause of cancer death worldwide. Chronic hepatitis due to HBV and HCV infection are two major risk factors for HCC worldwide.
Cuestas, María Luján, Mathet, Veronica Lidia, Oubiña, Jose Raul   +2 more
core   +1 more source

Emerging Therapies for Hepatocellular Carcinoma (HCC)

Cancers, 2022
Simple Summary Primary liver cancer, also known as Hepatocellular carcinoma (HCC), is considered to be a major global health challenge. Due to delays in diagnosis at early asymptomatic stages, HCC reaches a severe aggressive stage, thereby having a ...
Eesha Chakraborty, D. Sarkar
semanticscholar   +1 more source

ZNF561 antisense RNA 1 contributes to angiogenesis in hepatocellular carcinoma through upregulation of platelet-derived growth Factor-D

Chinese Journal of Physiology, 2022
Hepatocellular carcinoma is a common malignant tumor with high recurrence rate. Long non-coding RNA (lncRNA) ZNF561 antisense RNA 1 (ZNF561-AS1) functions as an oncogenic lncRNA to promote the tumorigenesis of colorectal cancer. The role of ZNF561-AS1 in
Jihu Zheng, Zijian Guo, Zhanchao Wen, Huikang Chen   +3 more
doaj   +1 more source

A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma. [PDF]

, 2015
Hepatocellular carcinoma (HCC), the second leading cause of cancer deaths worldwide, is difficult to treat and highly lethal. Since HCC is predominantly diagnosed in patients with cirrhosis, treatment planning must consider both the severity of liver ...
Busuttil, Ronald W, Faltermeier, Claire, Zarrinpar, Ali   +2 more
core   +2 more sources

Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases

Clinical Liver Disease, 2019
and Scope This guidance provides a data-supported approach to the diagnosis, staging, and treatment of patients diagnosed with hepatocellular carcinoma (HCC). A guidance document is different from a guideline.
J. Marrero, L. Kulik, C. Sirlin, A. Zhu, R. Finn, M. Abecassis, L. Roberts, J. Heimbach   +7 more
semanticscholar   +1 more source

Management of hepatocellular carcinoma: An update

Hepatology, 2011
Since the publication of the American Association for the Study of Liver Diseases (AASLD) practice guidelines on the management of hepatocellular carcinoma (HCC) in 2005, new information has emerged that requires that the guidelines be updated.
J. Bruix, M. Sherman
semanticscholar   +1 more source

MLN2238 exerts its anti-tumor effects via regulating ROS/JNK/mitochondrial signaling pathways in intrahepatic cholangiocarcinoma

Frontiers in Pharmacology, 2022
Background: Intrahepatic Cholangiocarcinoma (iCCA) is a highly malignant tumor with limited treatment options that contributes largely to cancer-related deaths worldwide.
Hao Xu, Hao Xu, Hao Xu, Hao Xu, Hao Xu, Hao Xu, Guangyu Xu, Guangyu Xu, Guangyu Xu, Guangyu Xu, Guangyu Xu, Guangyu Xu, Qianhui Xu, Qianhui Xu, Qianhui Xu, Qianhui Xu, Qianhui Xu, Qianhui Xu, Chang Xu, Chang Xu, Chang Xu, Chang Xu, Chang Xu, Chang Xu, Xiaohu Zhou, Yang Bai, Yang Bai, Yang Bai, Yang Bai, Yang Bai, Yang Bai, Lu Yin, Yuan Ding, Yuan Ding, Yuan Ding, Yuan Ding, Yuan Ding, Yuan Ding, Weilin Wang, Weilin Wang, Weilin Wang, Weilin Wang, Weilin Wang, Weilin Wang   +43 more
doaj   +1 more source

The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers. [PDF]

, 2011
Encapsulation of drugs within nanocarriers that selectively target malignant cells promises to mitigate side effects of conventional chemotherapy and to enable delivery of the unique drug combinations needed for personalized medicine.
Ashley, Carlee E, Brinker, C Jeffrey, Brown, Page A, Carnes, Eric C, Carroll, Nick J, Carter, Mark B, Chackerian, Bryce, Dunphy, Darren R, Durfee, Paul N, Evans, Deborah G, Hanna, Tracey N, Jiang, Xingmao, Liu, Juewen, Padilla, David, Parikh, Atul N, Peabody, David S, Petsev, Dimiter N, Phillips, Brandy, Phillips, Genevieve K, Wharton, Walker, Willman, Cheryl L   +20 more
core   +2 more sources

Elevated N‐methyltransferase expression induced by hepatic stellate cells contributes to the metastasis of hepatocellular carcinoma via regulation of the CD44v3 isoform

Molecular Oncology, 2019
The cross‐talk between hepatic stellate cells (HSCs) and hepatic carcinoma cells contributes to hepatocellular carcinoma (HCC) progression, but the underlying mechanism is largely unknown.
Jie Li, Song You, Sheng Zhang, Qing Hu, Fuqiang Wang, Xiaoqin Chi, Wenxiu Zhao, Chengrong Xie, Changmao Zhang, Yaqi Yu, Jianmin Liu, Yue Zhao, Pingguo Liu, Yi Zhang, Xujin Wei, Qiu Li, Xiaomin Wang, Zhenyu Yin   +17 more
doaj   +1 more source

Liver resection or combined chemoembolization and radiofrequency ablation improve survival in patients with hepatocellular carcinoma [PDF]

, 2007
Background/ Aims: To evaluate the long-term outcome of surgical and non-surgical local treatments of patients with hepatocellular carcinoma (HCC). Methods: We stratified a cohort of 278 HCC patients using six independent predictors of survival according ...
Angelika Schrader, Bloomston M, Bosch FX, Burkhard Göke, Castells A, Christian Graeb, Christoph Jüngst, Curley SA, Dieter Jüngst, Florian Löhe, Franco D, Goldberg SN, Gundula Straub, Horst-Günter Rau, Karl-Walter Jauch, Kotoh K, Livraghi T, Livraghi T, Livraghi T, Maximilian Reiser, Qian J, Ralf-Thorsten Hoffmann, Rolf Schauer, Rossi S, Rossi S, Ryder SD, Sasaki Y, Selin Dogan, Takenaka K, Thomas Helmberger, Tobias Jakobs, Tobias Waggershauser, Wolfgang H. Caselmann   +32 more
core   +1 more source